Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Add as a preferred source on Google
AbbVie pharmaceutical company announced on Wednesday, Dec. 6, that it will buy Cerevel Therapeutics. This deal is the company's latest attempt to expand its drug pipeline, as its best-selling treatments are currently facing generic competition.
Share Prices Soar with the Buyout Deal
According to CNBC, the share prices of Cerevel Therapeutics shot up to 16% at the close on Wednesday. This is equivalent to almost $43 per share, just a little below the purchase price of over $8 billion.
On the other hand, AbbVie's were said to have slightly gone down by less than 1% in the extended trading. These changes in the share prices show that the acquisition negotiations between the companies have a slight effect on their value.
Agreed Terms of the Deal
AbbVie said that under the agreed terms of the transaction, it will buy all the outstanding shares of Cerevel Therapeutics for the price of $45.00 per share, which will be paid in cash. The deal values the neuroscience drugmaker at about $8.7 billion.
It was mentioned that the companies' respective boards of directors have already greenlighted the deal. This transaction is expected to be completed by mid-2024, subject to regulatory approvals, Cerevel shareholders' approval, and other customary closing conditions.
"Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade," AbbVie's chairman and chief executive officer, Richard A. Gonzalez, said in a press release. "AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."
Ron Renaud, Crevel Therapeutics' president and chief executive officer, commented, "Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases."
Photo by: Abbvie Media Resources
